1. GonzalezR, AtaideR, NanicheD, MenendezC, MayorA (2012) HIV and malaria interactions: where do we stand? Expert Rev Anti Infect Ther 10: 153–165.
2. ter KuileFO, PariseME, VerhoeffFH, UdhayakumarV, NewmanRD, et al. (2004) The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg 71: 41–54.
3. UnekeCJ, OgbonnaA (2009) Malaria and HIV co-infection in pregnancy in sub-Saharan Africa: impact of treatment using antimalarial and antiretroviral agents. Trans R Soc Trop Med Hyg 103: 761–767.
4. van EijkAM, AyisiJG, ter KuileFO, MisoreAO, OtienoJA, et al. (2003) HIV increases the risk of malaria in women of all gravidities in Kisumu, Kenya. AIDS 17: 595–603.
5. MayorA, KumarU, BardajiA, GuptaP, JimenezA, et al. (2013) Improved pregnancy outcomes in women exposed to malaria with high antibody levels against Plasmodium falciparum. J Infect Dis 207: 1664–1674.
6. MenendezC, D'AlessandroU, ter KuileFO (2007) Reducing the burden of malaria in pregnancy by preventive strategies. Lancet Infect Dis 7: 126–135.
7. MenendezC, BardajiA, SigauqueB, RomagosaC, SanzS, et al. (2008) A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic. PLoS ONE 3: e1934.
8. WHO (2012) Intermittent Preventive Treatment of malaria in pregnancy using Sulfadoxine-Pyrimethamine (IPTp-SP). Updated WHO Policy Recommendation. WHO Available: http://www.who.int/malaria/iptp_sp_updated_policy_recommendation_en_102012.pdf
9. WHO (2004) A strategic framework for malaria prevention and control during pregnancy in the African region. Geneva: World Health Organization. AFR/MAL/04/01.
10. WHO (2013) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Recommendations for a public health approach June 2013. Geneva: World Health Organization.
11. SeveneE, GonzalezR, MenendezC (2010) Current knowledge and challenges of antimalarial drugs for treatment and prevention in pregnancy. Expert Opin Pharmacother 11: 1277–1293.
12. WardSA, SeveneEJ, HastingsIM, NostenF, McGreadyR (2007) Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis 7: 136–144.
13. DaramolaOO, AlonsoPL, O'DempseyTJ, TwumasiP, McArdleTF, et al. (1991) Sensitivity of Plasmodium falciparum in The Gambia to co-trimoxazole. Trans R Soc Trop Med Hyg 85: 345–348.
14. AnglaretX, MessouE, OuassaT, ToureS, Dakoury-DogboN, et al. (2003) Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Cote d'Ivoire. AIDS 17: 575–584.
15. RamharterM, WernsdorferWH, KremsnerPG (2004) In vitro activity of quinolines against Plasmodium falciparum in Gabon. Acta Trop 90: 55–60.
16. UhlemannAC, RamharterM, LellB, KremsnerPG, KrishnaS (2005) Amplification of Plasmodium falciparum multidrug resistance gene 1 in isolates from Gabon. J Infect Dis 192: 1830–1835.
17. AubouyA, FievetN, BertinG, SagboJC, KossouH, et al. (2007) Dramatically decreased therapeutic efficacy of chloroquine and sulfadoxine-pyrimethamine, but not mefloquine, in southern Benin. Trop Med Int Health 12: 886–894.
18. CDC (2011) Update: new recommendations for mefloquine use in pregnancy. Available: http://www.cdc.gov/malaria/new_info/2011/mefloquine_pregnancy.html. Accessed July 2013.
19. FDA (2013) FDA Drug Safety Communication: FDA approves label changes for antimalarial drug mefloquine hydrochloride due to risk of serious psychiatric and nerve effects. Available: http://wwwfdagov/Drugs/DrugSafety/ucm362227htm. Accessed July 2013.
20. McGreadyR, ChoT, HkirijaroenL, SimpsonJ, ChongsuphajaisiddhiT, et al. (1998) Quinine and mefloquine in the treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy. Ann Trop Med Parasitol 92: 643–653.
21. BriandV, BotteroJ, NoelH, MasseV, CordelH, et al. (2009) Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. J Infect Dis 200: 991–1001.
22. Denoeud-NdamL, ClementMC, BriandV, AkakpoJ, AgossouVK, et al. (2012) Tolerability of mefloquine intermittent preventive treatment for malaria in HIV-infected pregnant women in Benin. J Acquir Immune Defic Syndr 61: 64–72.
23. Denoeud-NdamL, ZannouDM, FourcadeC, Taron-BrocardC, PorcherR, et al. (2014) Cotrimoxazole prophylaxis versus mefloquine intermittent preventive treatment to prevent malaria in HIV-infected pregnant women: two randomized controlled trials. J Acquir Immune Defic Syndr 65: 198–206.
24. van EijkAM, AyisiJG, ter KuileFO, OtienoJA, MisoreAO, et al. (2004) Effectiveness of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in western Kenya: a hospital-based study. Trop Med Int Health 9: 351–360.
25. GonzálezR, Mombo-NgomaG, OuédraogoS, KakolwaMA, AbdullaS, et al. (2014) Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-negative women: a multicentre randomized controlled trial. PLoS Med 11: e1001733.
26. Ministry of Health and Social Welfare-The United Republic of Tanzania (2007) National Guidelines Prevention of Mother-to-Child Transmission of HIV. Ministry of Health of The United Republic of Tanzania.
27. Ministry of Health-Republic of Kenya (2009) Guidelines for the prevention of Mother to Child transmission (PMTCT) of HIV/AIDS in Kenya. Ministry of Health-Kenya.
28. Ministério da Saúde-República de Moçambique (2013) Introduçao de Novas Normas para o seguimiento do paciente HIV positivo. Direcçao Nacional de Assistencia Médica Ministério da Saúde de Moçambique.
29. BallardJL, KhouryJC, WedigK, WangL, Eilers-WalsmanBL, et al. (1991) New Ballard Score, expanded to include extremely premature infants. J Pediatr 119: 417–423.
30. GreenwoodAM, ArmstrongJR, ByassP, SnowRW, GreenwoodBM (1992) Malaria chemoprophylaxis, birth weight and child survival. Trans R Soc Trop Med Hyg 86: 483–485.
31. PlancheT, KrishnaS, KombilaM, EngelK, FaucherJF, et al. (2001) Comparison of methods for the rapid laboratory assessment of children with malaria. Am J Trop Med Hyg 65: 599–602.
32. SwysenC, VekemansJ, BrulsM, OyakhiromeS, DrakeleyC, et al. (2011) Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine. Malar J 10: 223.
33. AlonsoPL, SmithT, SchellenbergJR, MasanjaH, MwankusyeS, et al. (1994) Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 344: 1175–1181.
34. MayorA, Serra-CasasE, BardajiA, SanzS, PuyolL, et al. (2009) Sub-microscopic infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant women. Malar J 8: 9.
35. OrdiJ, IsmailMR, VenturaPJ, KahigwaE, HirtR, et al. (1998) Massive chronic intervillositis of the placenta associated with malaria infection. Am J Surg Pathol 22: 1006–1011.
36. RogersonSJ, MkundikaP, KanjalaMK (2003) Diagnosis of Plasmodium falciparum malaria at delivery: comparison of blood film preparation methods and of blood films with histology. J Clin Microbiol 41: 1370–1374.
37. ZouG (2004) A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 159: 702–706.
38. BardajiA, SigauqueB, BruniL, RomagosaC, SanzS, et al. (2008) Clinical malaria in African pregnant women. Malar J 7: 27.
39. TobinJ (1958) Estimation of relationships for limited dependent variables. Econometrica 26: 24–36.
40. Wooldridge JM (2012) Introductory econometrics: a modern approach. 5th edition. Cengage Learning.
41. WHO (2000) Safety monitoring of medicinal products. Guidelines for setting up and running a pharmacovigilance centre. WHO the Uppsala Monitoring Centre.
42. LadnerJ, LeroyV, SimononA, KaritaE, BogaertsJ, et al. (2002) HIV infection, malaria, and pregnancy: a prospective cohort study in Kigali, Rwanda. Am J Trop Med Hyg 66: 56–60.
43. RollinsNC, CoovadiaHM, BlandRM, CoutsoudisA, BennishML, et al. (2007) Pregnancy outcomes in HIV-infected and uninfected women in rural and urban South Africa. J Acquir Immune Defic Syndr 44: 321–328.
44. MenéndezC, RomagosaC, IsmailMR, CarrilhoC, SauteF, et al. (2008) An autopsy study of maternal mortality in Mozambique: the contribution of infectious diseases. PLoS Med 5: e44.
45. ZabaB, CalvertC, MarstonM, IsingoR, Nakiyingi-MiiroJ, et al. (2013) Effect of HIV infection on pregnancy-related mortality in sub-Saharan Africa: secondary analyses of pooled community-based data from the network for Analysing Longitudinal Population-based HIV/AIDS data on Africa (ALPHA). Lancet 381: 1763–1771.
46. SappenfieldE, JamiesonDJ, KourtisAP (2013) Pregnancy and susceptibility to infectious diseases. Infect Dis Obstet Gynecol 2013: 752852.
47. AlonsoPL, LindsaySW, Armstrong SchellenbergJR, KeitaK, GomezP, et al. (1993) A malaria control trial using insecticide-treated bed nets and targeted chemoprophylaxis in a rural area of The Gambia, west Africa. 6. The impact of the interventions on mortality and morbidity from malaria. Trans R Soc Trop Med Hyg 87 Suppl 2: 37–44.
48. NostenF, ter KuileF, MaelankiriL, ChongsuphajaisiddhiT, NopdonrattakoonL, et al. (1994) Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J Infect Dis 169: 595–603.
49. SchlagenhaufP, AdamcovaM, RegepL, SchaererMT, RheinHG (2010) The position of mefloquine as a 21st century malaria chemoprophylaxis. Malar J 9: 357.
50. SteketeeRW, WirimaJJ, SlutskerL, KhoromanaCO, HeymannDL, et al. (1996) Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. Am J Trop Med Hyg 55: 50–56.
51. GonzalezR, HellgrenU, GreenwoodB, MenendezC (2014) Mefloquine safety and tolerability in pregnancy: a systematic literature review. Malar J 13: 75.
52. KhaliqY, GallicanoK, TisdaleC, CarignanG, CooperC, et al. (2001) Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers. Br J Clin Pharmacol 51: 591–600.
53. Byakika-KibwikaP, LamordeM, MayitoJ, NabukeeraL, NamakulaR, et al. (2012) Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother 67: 2213–2221.
54. Byakika-KibwikaP, LamordeM, Okaba-KayomV, Mayanja-KizzaH, KatabiraE, et al. (2012) Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults. J Antimicrob Chemother 67: 1217–1223.
55. GermanP, ParikhS, LawrenceJ, DorseyG, RosenthalPJ, et al. (2009) Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr 51: 424–429.
56. KiangTK, WilbyKJ, EnsomMH (2014) Clinical Pharmacokinetic Drug Interactions Associated with Artemisinin Derivatives and HIV-Antivirals. Clin Pharmacokinet 53: 141–153.
57. KredoT, MauffK, Van der WaltJS, WiesnerL, MaartensG, et al. (2011) Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. Antimicrob Agents Chemother 55: 5616–5623.
58. BrachmanPSJr, MetchockB, KozarskyPE (1992) Effects of antimalarial chemoprophylactic agents on the viability of the Ty21a typhoid vaccine strain. Clin Infect Dis 15: 1057–1058.
59. HorowitzH, CarbonaroCA (1992) Inhibition of the Salmonella typhi oral vaccine strain, Ty21a, by mefloquine and chloroquine. J Infect Dis 166: 1462–1464.
60. AdachiE, KoibuchiT, ImaiK, KikuchiT, KogaM, et al. (2012) Favourable outcome of progressive multifocal leukoencephalopathy with mefloquine treatment in combination with antiretroviral therapy in an HIV-infected patient. Int J STD AIDS 23: 603–605.
61. GoftonTE, Al-KhotaniA, O'FarrellB, AngLC, McLachlanRS (2011) Mefloquine in the treatment of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry 82: 452–455.
62. MoensterRP, JettRA (2012) Mirtazapine and mefloquine therapy for progressive multifocal leukoencephalopathy in a patient infected with human immunodeficiency virus. Am J Health Syst Pharm 69: 496–498.
63. EzeamamaA, DugganC, ManjiK, SpiegelmanD, HertzmarkE, et al. (2014) Clinical malaria diagnosis in pregnancy in relation to early perinatal mother-to-child transmission of HIV: a prospective cohort study. HIV Med 15: 276–285.
64. UNAIDS/WHO (2010) Global report: UNAIDS report on the global AIDS Epidemic 2010. Joint United Nations Programme on HIV/AIDS UNAIDS/10.11E: (JC1958E).
65. WHO (2005) Technical Consultation on Malaria and HIV Interactions and Public Health Policy Implications (2004: Geneva, Switzerland) Malaria and HIV interactions and their implications for public health policy. Geneva: WHO.
66. MPAC (2013) Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of September 2013 meeting. Malar J 12: 456.